Actuate's Elraglusib Enters BEACON2 Pediatric Neuroblastoma Trial, Capital-Efficient Development
ACTU sits 15% above its 52-week low of $1.58.
Summary
Actuate Therapeutics' drug Elraglusib has been selected for evaluation in the BEACON2 Phase 1/2 trial for high-risk pediatric neuroblastoma. This is a significant development for the company's lead asset, especially as the trial is sponsored by Cancer Research UK, providing a capital-efficient pathway to generate critical clinical data. This positive pipeline progress is crucial given the company's recent going concern warnings, which indicated cash to fund operations only until July 2026. Elraglusib previously showed a complete response in a neuroblastoma patient in a Phase 1 study and has FDA Rare Pediatric Disease designation.
At the time of this announcement, ACTU was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.5M. The 52-week trading range was $1.58 to $9.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.